phocytes in the GVL response: relapse rates are higher after T cell-depleted BMT 3-5 while remissions can be reinduced with donor lymphocyte transfusions in patients who relapse We studied patients relapsing with myeloid leukemias following allogeneic bone marrow transplantation after BMT. 6 There is also experimental evidence for the involvement of NK cells in GVL. 7,8 It is therefore generally (BMT) for evidence of immune escape by clonal evolution of the leukemia. Relapsed cells from four out of assumed that leukemic relapse after BMT is related to qualitative or quantitative defects in donor immune funcfive patients had a reduced ability to stimulate proliferation of lymphocytes from an HLA-mismatched tion. 9 One reason for the failure of GVL could be immune escape by clonal evolution in the leukemia which selects responder. There was decreased susceptibility to lysis by CTL in three and reduced susceptibility to NKmalignant cells that can avoid immune recognition. Malignancies that resist the effects of cellular immunotherapy mediated lysis in one. Relapsed leukemias had marked alterations in expression of critical surface molecules have been demonstrated in murine models 10,11 and suggested in man. 12 As described in other tumors, the failure involved in immune responsiveness. Three had decreased expression of MHC class I and II, with no to recognize leukemia cells directly may result from lack of expression of MHC-complex molecules, 13-16 lack of a change or increase in CD54 (ICAM-1) or CD80 (B7.1). None of these responded to treatment with donor suitable tumor antigen, 17 defective antigen processing, 18, 19 production of inhibitors that actively suppress antitumor lymphocytes. Three patients showed no change, or increased expression of MHC with no change or response, 20 lack of the appropriate costimulatory molecules necessary to induce an immune response, [21] [22] [23] downreguldecrease in ICAM-1 or B7.1. Two achieved remissionone in response to donor lymphocytes and one following ation of CD54 (ICAM-1) 24, 25 or lack of expression of CD95 (Fas) antigen, 26,27 a cell surface molecule involved in withdrawal of cyclosporine. In one patient transplanted with myelodysplastic syndrome in transformation, apoptosis.
production of inhibitors that actively suppress antitumor lymphocytes. Three patients showed no change, or increased expression of MHC with no change or response, 20 lack of the appropriate costimulatory molecules necessary to induce an immune response, [21] [22] [23] downreguldecrease in ICAM-1 or B7.1. Two achieved remissionone in response to donor lymphocytes and one following ation of CD54 (ICAM-1) 24, 25 or lack of expression of CD95 (Fas) antigen, 26, 27 a cell surface molecule involved in withdrawal of cyclosporine. In one patient transplanted with myelodysplastic syndrome in transformation, apoptosis.
In this report, we compared the immunogenicity of interferon-gamma upregulated expression of MHC molecules in relapsed cells and increased their stimumyeloid leukemia cells before BMT and at relapse in patients with AML, myelodysplastic syndrome (MDS) and latory capacity and target susceptibility to unmatched responder lymphocytes. These results suggest that CML. Using mismatched responder lymphocytes we used proliferative and cytotoxic alloimmune responses to detect immune escape through clonal evolution of the leukemia is a common occurrence in patients who relapse with and quantitate defects in lymphocyte stimulation and target susceptibility of leukemia cells. We also compared the myelogenous leukemias after BMT. Keywords: BMT; GVL; relapse; CML; AML; immune immunophenotype of the leukemia before and after relapse using a direct immunofluorescence assay to measure critical escape molecules involved in antigen presentation and lymphocyte responses: MHC class I and II (DR and DQ), ICAM-1, Fas and B7.1. We present data supporting the possibility that Although allogeneic BMT from an HLA-identical sibling leukemias relapsing after BMT are clonally selected to donor has a high curative potential in the treatment of evade donor-derived immune control. myeloid leukemias, relapse of the disease occurs in about 20% of acute myeloid leukemias (AML) and 15% of chronic myelogenous leukemias (CML). 1, 2 The risk of Patients and methods relapse has been linked to the degree to which the allograft can exert a graft-versus-leukemia (GVL) effect against
Patients and donors residual leukemia remaining after the myeloablative preparative regimen. Clinical data supports a role for T lymBetween September 1993 and January 1996, 28 patients with acute or chronic myeloid leukemia or myelodysplastic syndrome received a bone marrow transplant from an HLA- + cells/kg on days 30 and 45 post-BMT. All were cultured with 10 7 5000 cGY irradiated stimulating patients received cyclosporin GVHD prophylaxis from day pre-BMT cells in 25-cm 2 flasks containing 10 ml CM + −4 to day +100 post-BMT. The cells were separated using 10% HS. Recombinant interleukin-2 (IL-2; Biosource) was Ficoll-Hypaque gradient-density (Organon Teknika, Duradded to the cultures on day 3 and day 7 at 60 IU/ml. On ham, NC, USA) and subsequently frozen in RPMI-1640 day 10, lymphocytes were harvested, resuspended, and sericomplete medium (CM, 25 mm HEPES buffer, 2 mm l-glually diluted to be used in the CTL assay as effectors. tamine, 20% gentamicin; GIBCO BRL, Gaithersburg, MD, USA) supplemented with 20% heat inactivated fetal bovine Natural killer (NK) cell activity: Fresh PBMCs isolated serum (FBS; Atlanta Biologicals, Norcross, GA, USA), or from the heparinized peripheral blood of a normal individ-20% heat-inactivated pooled human AB serum (HS; Pelual donor D2 were separated by gradient-density using FicFreez, Brown Deer, WI, USA) and 10% DMSO according oll-Hypaque and used immediately as effectors in the cytoto standard protocols. Before use, the cells were thawed, toxicity assay against pre-BMT and relapsed leukemia washed and suspended in CM + 10% HS. cells. AML = acute myeloid leukemia; CML = chronic myeloid leukemia; CMML = chronic myelomonocytic leukemia; tMDS = myelodysplastic syndrome in transformation; CP = chronic phase; AP = accelerated phase; BC = blast crisis; MF = myelofibrosis; CsA = cyclosporin A; DLT = donor lymphocyte transfusion; NA = not available; IL-2 = interleukin-2; IFN-␣ = interferon-alpha; NR = no response; CR = cytogenetic remission. pre-and post-BMT leukemic stimulator/target cells was comparable, we performed differential counts of stained and HLA class II DR, CD54, CD80 and CD95 (all from cytospins. No important differences in the cellular comImmunoTech, Marseille, France). Phycoerythrin (PE)-conposition of the leukemic stimulator/target cells were found jugated anti-CD33 (ImmunoTech) was used to select for ( 
Susceptibility to lysis of leukemia cells by CTLs before and after BMT
Irradiated pre-transplant leukemia samples were used to stimulate the lymphocytes from the HLA-mismatched responder D1. After 10 days of culture with IL-2 addition and re-feeding, the responder cells were tested for their ability to lyse paired pre-and post-transplant leukemia samples. Results are shown in Figure 2 . At an E:T ratio of 24:1 there was a 27 to 44% lysis of pre-transplant targets. Lysis of post-transplant leukemias was markedly reduced in three patients P1, P2 and P5 (4.6, 6.6 and 3.6% respectively). There was no change in the target susceptibility in patients P3 and P4. In patient P2, incubation of the post-transplant but not the pre-transplant leukemia targets with IFN-␥ induced an increase in the lysis of the post- transplant leukemia to almost pre-BMT levels (E:T at 24:1 rose from 6.6 to 30%). There was no increase in the lytic Fresh normal PBMC was used as a source of NK cells. Standard NK assays were carried out at three E:T ratios, against paired pre-and post-transplant leukemia cells using K562 cells as a positive control. The results for four (c.p.m. Ͻ 100 c.p.m.). Leukemias pre-transplant differed in patients tested are shown in Figure 3 . In three both pretheir ability to stimulate a third party with absolute c.p.m.
and post-BMT leukemia samples gave comparable results varying from 6000 ± 1000 to 40 000 ± 2000. Post-transand were lysed more readily than K562 cells. In one (P4) plant stimulation was generally lower from Ͻ 100 to the relapsed sample was lysed less effectively than K562 27 5000 ± 2000 c.p.m. Leukemia cells at relapse post-BMT cells and considerably less than the pre-transplant leukemia. induced lower proliferative responses than the pre-transplant leukemia in four patients with a ratio of pre:post stimulation indices of 1:0.04 (P1), 1:0.59 (P2), 1:0.7 (P3)
Phenotype of leukemia cells before and after BMT and 1:0.07 (P4). One patient P5 who was transplanted in blast crisis of CML and relapsed into blast crisis induced
The alterations in stimulatory ability and target susceptibility of leukemia at relapse after BMT prompted us to comparable low proliferation before and after transplant (6000 c.p.m.).
examine the possibility that escape from immune surveillance had occurred by downregulation in surface molecules Pre-transplant and post-transplant leukemia samples were incubated with IFN-␥ (10 3 U/ml) for 24 h to test for involved in immune responses. We therefore compared expression of MHC (class I and class II), CD45 (ICAMinduction of stimulatory ability to the third party lymphocytes. IFN-␥ treatment of P2 relapsed cells induced a seven-1), CD80 (B7.1) and CD95 (Fas) in CD33 + gated cell populations of pre-transplant and post-transplant relapsed leukefold increase in stimulatory capacity (Figure 1 inset) . There was no increase in the stimulatory capacity of the other mias. An additional patient (P6) was also studied. Results of flow cytometry were expressed as % positive cells and relapsed leukemias. Comparing pre-and post-relapse samples, there were three discernable alterations in HLA DR expression: (1) lower positive cells and in most cases the percentage of positive cells was over 90% (Figure 4a ). The fluorescence intensity percentage of DR expressing cells at relapse after BMT with almost undetectable FI at relapse (P1, P2 and P3); (2) (FI) of MHC class I was in general much lower than that of EBV-LCL cells. In P1, P2 and P3, FI was in the region slightly higher percentage of cells expressing HLA DR after BMT but with extremely low FI (P4 and P6); and (3) of 30% of EBV-LCL pre-transplant, and fell to barely detectable levels after BMT. In P3, the post-BMT sample P5 with high DR expression and high FI pre-and post-BMT. IFN-␥ had no effect on the percentage of cells also showed a major reduction in the percentage of cells expressing MHC class I. P4 and P5 showed no difference expressing HLA DR but increased FI in P5 (pre-and post-BMT) and P1 post-BMT. in FI before and after BMT. An increase in MHC class I expression from 60 to 100% post-transplant with a corresponding increase in FI occurred in P6. Incubation with HLA class II DQ: Compared with EBV-LCL the % and the FI of leukemia cells expressing HLA DQ was generally IFN-␥ modestly increased FI in most samples. very low (Figure 4c ). Only P3 and P5 had more than 10% and post-relapse samples P1, P4, P5 and P6 had lower % expression and usually lower FI after BMT, whereas P2 cells expressing DQ, with FI above the background for K562 cells. Comparing pre-and post-BMT samples, there and P3 showed increased % expression after BMT but decreased FI. IFN-␥ modestly increased B7.1 expression were two changes: (1) low to undetectable % expression and FI (P1, P2, P4 and P6); and (2) and loss of susceptibility to CTL, but not NK cytotoxicity
No change (P4) or an increase in MHC class I and II expression (P5 and P6):
Loss of susceptibility to CTL or in the two patients tested, was associated with no significant change, or an increase in B7.1, ICAM-1 and Fas. None of NK cells, with low or reduced stimulatory capacity, was associated with loss of B7.1, no change or loss or ICAMthese three patients responded to treatment with donor lymphocytes.
1 and variable changes in Fas. Two out of three patients responded to immune manipulation (one to DLT (P4)) and geneic BMT and the effect of immune manipulation to induce remissions in patients relapsing after BMT (T cellone to withdrawal of cyclosporine immunosuppression.
depletion, DLT, stopping CsA, IFN-␣) strongly supports a role of the donor immune system in regulating residual leukemia after BMT. Leukemic relapse following alloDiscussion geneic BMT is usually attributed to a failure of the preparative regimen or the donor immune system to control It has long been considered that malignant cells may undergo clonal selection to escape from immune regulation residual disease. An alternative possibility however is that the leukemia may have evolved to escape from immune and there is circumstantial evidence supporting this hypothesis.
10-12 The demonstration of a GVL effect following allocontrol under the strong negative selection pressure of an At relapse: ↑ = increased; ↓ = decreased; 0 = no change; L = no change but low; NT = not tested.
alloreactive donor immune system. Only one report has susceptibility to CTL lysis, but a reduced sensitivity to NK lysis with cells that were more resistant than K562 cells. associated leukemic relapse after allogeneic BMT with immune escape of the leukemia. 12 In this study, relapse Since there were no important differences in the composition of the stimulator/targets before and after relapse, the occurred after an HLA-haploidentical BMT in a patient with acute lymphocytic leukemia. The weak mixed lymobserved differences in immunogenicity between pre-BMT and relapsed leukemias could not be attributed to the phocyte culture and undetectable primary cell-mediated cytotoxicity responses of the donor to the post-BMT relapse stimulator/target cell composition (Table 3) .
In order further to define the changes in susceptibility cells suggested that the relapsed leukemia may have been selected in vivo for resistance to the donor immunity.
to immune attack, we quantitated major surface molecules involved in the immune response on pre-and post-BMT We argued that immune escape leading to relapse after BMT could occur either because the leukemia becomes leukemia samples. CD33 + cell fractions from CML and AML and MDS pre-transplant, showed some variation in nonstimulatory to donor T cells or ceases to be susceptible to destruction from effector T cells or NK cells. We therethe percentage of marked cells and fluorescence intensity. Mostly the expression of MHC molecules, costimulatory fore examined six patients with various myeloid leukemias who relapsed with leukemia after HLA-matched sibling molecules and Fas, were in an intermediate range between the highly expressing EBV LCL controls and the low or BMT, comparing pre-transplant leukemia with the relapsed leukemia, for its ability to stimulate an immune response absent expression found in K562 cells. Leukemias relapsing after transplantation showed two broad patterns of alterand to be a target for T cell and NK cell attack. We showed that in four of five leukemias, the ability to stimulate a third ation in surface molecule expression: (1) downregulation of MHC class I and II with upregulation of ICAM-1 and party lymphocyte proliferative responses was significantly reduced. In the fifth patient the stimulatory capacity of the upregulation or high expression of B7.1; and (2) increase or no change in MHC expression but decrease or no change leukemia was low pre-transplant and remained unchanged. By using the normal donor as an HLA-matched control for in ICAM-1 and B7.1. Expression of Fas antigen was variably altered at relapse (in four it was unchanged or fell but the third party responder, we showed that the response was significantly lower than that of a normal stimulator cell.
remained highly expressed; in two it was increased). Both loss of MHC expression or loss of costimulation from Using a similar approach we used pre-transplant leukemia cells to stimulate CTL from an HLA-mismatched normal ICAM-1 or B7.1 could explain the decreased ability of relapsed leukemia to stimulate T cell responses. These responder. (We chose pre-transplant cells to induce CTL, since they were shown to be capable of stimulating a third findings did not however readily explain the reduced susceptibility of the leukemias to CTL or NK mediated lysis. party proliferative response.) After 10 days, CTL generated in this way had no LAK activity as demonstrated by their
The decreased ability of the relapsed leukemia to stimulate an immune response and the increased ability to avoid inability to lyse K562 cells. However they showed specific cytotoxic activity to the stimulating leukemia. Using a cytotoxic damage from CTL or NK cells were consistent with the hypothesis that immune escape had occurred by second normal responder, the susceptibility to NKmediated lysis was also tested. Leukemia cells from all clonal evolution leading to relapse. In support of clonal evolution in the leukemia, was the observation of new patients before the BMT were susceptible to CTL lysis and more susceptible to NK lysis than K562 cells. In three of chromosomal abnormalities in P2, P3 and P4 and a change in morphology in P1 and P2. The alteration in the leukemia five patients tested, there was a reduction in the ability of CTL to lyse the post-transplant target, with conserved suscell type could be the result of selection of pre-existing leukemia sub-clones remaining after the preparative regiceptibility to NK lysis. One patient at relapse showed no change in target susceptibility and one showed an increased men or to mutations occurring after BMT. to treatment with donor lymphocytes, withdrawal of ceptibility. Since IFN-␥ upregulates MHC molecules 30 we
